CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 5. Effect of endocytosis inhibition by latrunculin A and of arachidonic acid supplementation on Fas/CD95 surface expression in Jurkat cells and in the sublines. Jurkat (left panels), Jurkat-ws (middle panels), or Jurkat-hp cells (right panels) were left untreated, were incubated for 1 h with 40 µg/ml of latrunculin A (+Latr, top panels), or were supplemented with 10 µM arachidonic acid bound to serum proteins for 48 h (+20:4, bottom panels). After the incubations, cells were stained at 4°C with FITC-labeled anti-Fas mAb SM1/23 and Fas/CD95 surface expression analyzed by flow cytometry. Diagrams shown are representative of at least three different experiments performed for each experimental condition.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation